A principle objective of both the MHRA and of pharmaceutical companies is to protect and improve the health of patients. When new information about the benefits and risks of a medicine become available it is often appropriate to make changes to the safety information for the product.
The GXP environment is evolving as digital technologies are increasingly being applied to the development and manufacture of medicines.
The MHRA Good Manufacturing/Good Distribution Practice Symposium will be held in London on the 11 to 14 November and in Glasgow on 26 to 27 November 2019. This post details how to secure your place and provides some information about what each of the sessions will include.
On 28 October 2019 the GCP inspectorate will be holding a roundtable discussion aimed at suppliers of electronic health records in both primary and secondary care (including commercial and non-commercial developers). This post details how to register your attendance for this event.
Details and links for new licence applications and variations.
Theft of medicines increases risk to public health - a look at what can be done to improve distribution security standards.
This month sees the close of the consultation on the application of Analytical Quality by Design to pharmacopoeial standards. We sat down with Peter and Stephen, pharmacopoeial scientists for the British Pharmacopoeia, to discuss why this consultation may prove vital …
A look at the hot topics relevant to non-commercial sponsors and investigator sites on the agenda for this event on 11 September in Manchester
Sharing experience from recent events to help you safeguard the legitimate supply chain and avoid risks to public health
Whether investigator site or sponsor, what can be done to ensure EHRs are fit for purpose to make clinical trials the best they can be.